HROW

Harrow, Inc. (HROW)
Healthcare • Drug Manufacturers - Specialty & Generic • $38.54 • MCap: 1,444,781,696 🌐
https://www.harrow.com • Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Buy Decision Core
Total Score
39
Business Quality
10
Financial Strength
8
Growth Outlook
1
Momentum
3
Price Action
Current
38.54
52W High
54.80
52W Low
29.03
Above 50DMA
40.84 (-5.62%)
Above 200DMA
41.29 (-6.66%)
Relative Strength
Relative Strength
0.05
RS 3M
0.16
RS 6M
0.06
RS 9M
-0.13
RS 12M
-0.02
Fundamentals
Revenue Growth
0.11%
Earnings Growth
0%
ROE
-1.16%
ROA
0.00%
Valuation
PE (Fwd)
14.08
PEG
0
P/B
94.93
Upside
75.14%
Risk
Beta
0.24
Short %
0.19
Risk Score
6.00
Analyst
Rating
strong_buy
Target
67.50
Beta
0.24
Analysts
0


Total Score
39
Upside
75.14%
Relative Strength
0.05
Beta
0.24
Why Buy?
  • PEG Ratio below 1 (attractive valuation)
  • Analyst upside exceeds 15%
Key Risks
  • Negative ROE
  • Weak long-term relative strength
Score Breakdown
Business
10
Financial
8
Growth
1
Valuation
11
Risk
2
Momentum
3
Technical
52W High: 54.80
52W Low: 29.03
Above 50DMA: -5.62%
Above 200DMA: -6.66%
Valuation
Forward PE: 14.08
PEG: 0
P/B: 94.93
Upside: 75.14%
Risk
Beta: 0.24
Short Float: 0.19%
ROE: -1.16%
ROA: 0.00%